$69 postpage LB

Market Update: S&P/ASX200 Ended in Red; APE Soared by 13.333%

  • July 29, 2020 10:32 PM AEST
  • Team Kalkine
Market Update: S&P/ASX200 Ended in Red; APE Soared by 13.333%

On 29th July 2020, the equity market of Australia ended in red, and S&P/ASX200 went down by 14.1 points to 6006.4. During the last five days, the index has lost 1.13%. S&P/ASX 200 Materials (Sector) settled at 14,270.0, reflecting a fall of 250.7 points. S&P/ASX 200 Information Technology (Sector) moved down by 1.56% to 1,629.2.

Gold MTF non-AMP

On ASX, the share price of AP Eagers Limited (ASX: APE) settled at $7.990 per share. The stock of PolyNovo Limited (ASX: PNV) stood at $2.270 per share with a rise of 3.182%.

Stock Performance (Source: ASX)

S&P/NZX50 settled the session at 11,599, reflecting a rise of 0.18%. The share price of New Talisman Gold Mines Limited (NZX: NTL) rose by 14.29% to NZ$$0.008 per share. The stock of Plexure Group Limited (NZX: PLX) inched up by 9.09% to NZ$1.320. However, the share price of Blackwell Global Holdings Limited (NZX: BGI) moved down by 15.00% to NZ$0.017 per share.

On the same day, the share price of Wellington Drive Technologies Limited (NZX: WDT) witnessed a fall of 5.71% on an intraday basis to NZ$0.066 per share. Also, the stock of T&G Global Limited (NZX: TGG) encountered a decline of 5.20% to NZ$2.550 per share.

Recently, we have written an article on Mount Burgess Mining NL (ASX:MTB), and the readers can view the content by clicking here.

AP Eagers Limited Finished 2019 Annual General Meeting on 29th July 2020.

AP Eagers Limited (ASX: APE) recently completed its 2019 Annual General Meeting, wherein all resolutions were passed on a poll. The Chairman of the company stated that the group recorded a statutory loss after tax amounting to $80.5 million for the year to December 31, 2019. The group managed to deliver underlying operating profit before tax of $100.4 million despite challenging market conditions.

PolyNovo Limited Ended in Green on Australian Securities Exchange.

PolyNovo Limited (ASX: PNV) recently advised the market that it has received funding of US$15 million from BARDA to support the Pivotal trial program of NovoSorb BTM. The company would make a modest co-funding and “in kind” contribution to the trial with the final budget to be announced after the US FDA approval.

With respect to the US, the company stated that June 2020 was the new record sales month.

The company has opened 7 new hospital accounts since the record sales month announced on 7th April.



The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK